Organon & Co. cotiza a 13.77 USD y tiene una capitalización bursátil de $3.6B. En los últimos 12 meses ha facturado $6.1B con un margen de flujo de caja libre del 8.7%. Cotiza a 6.4 veces su flujo de caja libre (P/FCF) y a un PER de 17.3. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception …
| Periodo | 2026-11 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.85 | $0.71 | $0.63 |
| Estimado | $0.88 | $1.07 | $0.85 | $0.73 |
| Sorpresa | — | -20.6% | -16.5% | -13.7% |
| Métrica | OGN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 53.3% | 57.0% | -3.7% |
| Operating Margin | — | -38.6% | — |
| Net Margin | 3.0% | -33.6% | +36.6% |
| FCF Margin | 8.7% | -13.9% | +22.5% |
| ROE | 24.9% | -40.4% | +65.3% |
| ROA | 1.4% | -32.0% | +33.5% |
| Current Ratio | 1.82 | 2.84 | -1.02 |
| Debt / Equity | 11.49 | 0.28 | +11.21 |